Chronic prostatitis and sclerosis of prostate. Predisposing factors for surgical complications.
DOI:
https://doi.org/10.52692/1857-0011.2022.3-74.22Keywords:
Chronic, non-bacterial, prostatitis, adenoprosin, prostate, sclerosisAbstract
Chronic nonbacterial prostatitis category III/chronic pelvic pain syndrome is detected in 90-95% of patients and depending on the disorders of proteolytic processes in the blood and prostate is subdivided into inflammatory (category IIIA) and non-inflammatory (category IIIB). The treatment of patients with chronic prostatitis must be complex, strictly differentiated and must provide for action on all etiological links and methods of treatment of CP. The paper determined the efficiency of entomological medication in chronic nonbacterial prostatitis and the contribution in preventing compli- cations in this category of patients. It has been found that the administration of adenoprosine in combination with the standard complex physiotherapy of chronic nonbacterial prostatitis category IIIA and B (inflammatory and non-inflam- matory) of the entomological preparation significantly increases the efficacy of the applied treatment, prevents or stops the evolution of chronic nonbacterial prostatitis consequences.
References
Bushman W. A., Jerde T. J. The role of prostate inflammation and fibrosis in lower urinary tract symptoms. Am J Physiol Renal Physiol. 2016; 311(4): F817–F821.
Cantiello F., Cicione A., Salonia A. et al. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology. 2013; 81(5):1018–1023.
Ghicavii V., Ciuhrii C., Ceban E., Dumbraveanu I. New Direction in the Treatment of Benign Prostate Hyperplasia Using Adenoprosin: Biologically Active Entomological Medicine In Urology, 2011, 78(3), OI10.1016/j. urology.2011.07.209 (IF 1,18)
Gorbunova E.N., Davydova D.A., Krupin V.N. Chronic inflammation and fibrosis as risk factors for prostatic intraepithelial neoplasias and prostate cancer. Modern technology in medicine. 2011; 1:79–83.
Gordon M.K., Hahn R.A. Collagens. Cell Tissue Res. 2010; 339:247–257.
He Y., Zeng H.Z., Yu Y., Zhang J.S. et al. Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis. Environ Toxicol Pharmacol. 2017; 54:120–124.
Hu Y., Niu X., Wang G. et al. Chronic prostatitis/ chronic pelvic pain syndrome impairs erectile function through increased endothelial dysfunction, oxidative stress, apoptosis, and corporal fibrosis in a rat model. Andrology. 2016;4(6):1209–1216. DOI: 10.1111/andr.12273.
Kadler K.E., Baldock C., Bella J., Boot-Handford R.P. Collagens at a glance. J Cell Sci. 2007; 120:1955–1958.
Ma J., Gharaee-Kermani M., Kunju L. et al. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol. 2012; 188:1375–1381.
Neimark A.I., Kiptilov A.V., Lapiy G.A. Clinical and pathological features of chronic prostatitis in chemical production workers. Urology. 2015; 3:68–73.
Nickel J.C., Roehrborn C.G., O’Leary M.P. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the reduce trial. Eur Urol. 2008; 54:1379–1384.
Rodriguez-Nieves J.A., Macoska J.A. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013; 10(9):546–550.
Wight T.N., Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol. 2011; 301: G950–955.
Wong L., Hutson P.R., Bushman W. Prostatic inflammation induces fibrosis in a mouse model of chronic bacterial infection. PLoS One. 2014; 9(6): e100770.
Wong L., Hutson P.R., Bushman W. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate. 2015; 75(1):23–32.
Zaitsev A.V., Pushkar D. Yu., Khodyreva L.A., Dudareva A.A. Chronic bacterial prostatitis, urinary disorders in men and prostate fibrosis. Urology. 2016; 4:114–120.
Думбравяну И., Банов П., Ариан Ю., Тэнасе А. Применение энтомологических препаратов в комплексном лечении больных хроническим простатитом и эректильной дисфункцией. 18 Конгресс ассоциации андрологов России. Дагомыс 23-25 мая 2019.
Думбрэвяну И., Гикавый В., Чебан Е., Тэнасе А. Лечение доброкачественной гиперплазии предстательной железы и воспалительных процессов простаты препаратом Аденопросин. В: Андрология и генитиальная хирургия. 2010, 2, c. 136-137, ISNN 2070 -9781.
Downloads
Published
License
Copyright (c) 2022 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
